Ingham, M., Mahoney, M. R., Remotti, F., Shergill, A., Dickson, M. A., Riedel, R. F., … Tap, W. D. (2020). A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Ingham, Matthew, Michelle R. Mahoney, Fabrizio Remotti, Ardaman Shergill, Mark Andrew Dickson, Richard F. Riedel, Steven Attia, et al. “A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Ingham M, Mahoney MR, Remotti F, Shergill A, Dickson MA, Riedel RF, et al. A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304). In: JOURNAL OF CLINICAL ONCOLOGY. 2020.

Ingham, Matthew, et al. “A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304).” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.

Ingham M, Mahoney MR, Remotti F, Shergill A, Dickson MA, Riedel RF, Attia S, Elias AD, Liebner DA, Agulnik M, Thornton KA, Monga V, Van Tine BA, Schwartz GK, Tap WD. A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304). JOURNAL OF CLINICAL ONCOLOGY. 2020.